Nelson Capital Management LLC Has $4.24 Million Stake in Stryker Co. (NYSE:SYK)

Nelson Capital Management LLC decreased its holdings in Stryker Co. (NYSE:SYK) by 2.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 11,777 shares of the medical technology company’s stock after selling 288 shares during the period. Nelson Capital Management LLC’s holdings in Stryker were worth $4,240,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of SYK. Dunhill Financial LLC raised its stake in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares in the last quarter. Centricity Wealth Management LLC acquired a new stake in Stryker in the fourth quarter valued at $30,000. BankPlus Trust Department bought a new position in Stryker during the 4th quarter worth $33,000. Darwin Wealth Management LLC acquired a new position in Stryker during the 3rd quarter worth about $36,000. Finally, Activest Wealth Management bought a new stake in shares of Stryker in the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of recent analyst reports. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Argus set a $450.00 price target on shares of Stryker in a research report on Monday, February 3rd. Piper Sandler reissued an “overweight” rating and issued a $420.00 price objective (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Finally, Royal Bank of Canada boosted their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Stock Up 0.7 %

SYK opened at $390.57 on Wednesday. The company has a 50 day moving average of $378.78 and a 200 day moving average of $370.22. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a market cap of $149.03 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the firm earned $3.46 earnings per share. On average, sell-side analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.